1817. Ceftaroline Fosamil for the Treatment of Hospital-acquired pneumonia (HAP) and Ventilator-associated pneumonia (VAP): CAPTURE study experience
Session: Poster Abstract Session: Respiratory Infections: Potpourri
Saturday, October 10, 2015
Room: Poster Hall
  • HAP-VAP[F1.01].pdf (491.8 kB)
  • Background: Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) are serious infections increasingly associated with resistant pathogens, including methicillin-resistant Staphylococcus aureus(MRSA).  CAPTURE is a multicenter registry study describing patients (pts) treated with ceftaroline fosamil (CPT-F) in the US. Clinical study experience for the use of CPT-F in treatment of pts with HAP/VAP, defined according to ATS/IDSA guidelines, is presented.

    Methods: Data were collected from participating sites by randomly ordered chart review between Sept 2013 and Feb 2015, which included demographics, disease characteristics, antibiotic use, location of care, pathogens isolated, and clinical response. Evaluable pts were those with a clinical outcome determined. Clinical success was defined as clinical cure or clinical improvement. 

    Results: In the evaluable population 44/1274 (3%) had HAP/VAP, 30 had HAP and 14 had VAP. Demographics: 57% male; mean age 60.5 years (SD ± 17.4, range 18–91); and 43% required mechanical ventilation. The most commonly reported co-morbidities were smoking, 52%; structural lung disease, 45%; and gastroesophageal reflux (GERD), 25%. Antibiotics were administered prior to CPT-F in 86%, most commonly vancomycin, 68%; piperacillin-tazobactam, 43%; and levofloxacin, 20%. Concurrent antibiotics were administered in 45% of pts; most commonly vancomycin, 14%. Most pts were treated in the ICU, 68%. The overall mean (± SD) duration of CPT-F therapy was 6.9 ± 3.4 days; 6.8 ± 3.3 days for ICU pts; and 7.2 ± 3.6 days for GHW pts. Ten pts, 23%, all treated in ICU, had associated bacteremia. Pathogens were isolated from 64% of pts; most commonly MRSA, 48% and Escherichia coli, 7%. Clinical success rates are shown in the table.

    Conclusion: Clinical success with CPT-F was favorable in pts with HAP/VAP, particularly considering co-morbidities, high level of acuity and ventilator dependence; and the fact that most received CPT-F as 2nd-line therapy.

    Clinical success rates

    n/N (%)


    34/44 (77)


    20/30 (67)


    14/14 (100)


    33/43 (77)


    17/23 (74)

    Structural lung disease

    16/20 (80)


    8/11 (73)


    20/24 (83)

    2nd-line therapy

    31/38 (82)

    Pathogen isolated

    18/28 (64)


    13/21 (62)

    George Udeani, PharmD, DSc, FCP, FCCP, Corpus Christi Medical Center, Corpus Christi, TX, David Guervil, PharmD, Memorial Hermann-Texas Medical Center, Houston, TX, Leonard B Johnson, MD, FIDSA, St John Hospital and Medical Center, Grosse Pointe Woods, MI and Keith Kaye, MD, MPH, FIDSA, FSHEA, Medicine, Wayne State University, Detroit, MI


    G. Udeani, Forest Plc: Consultant and Investigator , Consulting fee and Research grant

    D. Guervil, None

    L. B. Johnson, None

    K. Kaye, Actavis: Consultant , Investigator and Speaker's Bureau , Consulting fee , Research grant and Speaker honorarium

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.